OR WAIT 15 SECS
Seqirus, CSL Limited’s influenza vaccine business, announced the opening of their corporate headquarters in the United Kingdom.
CSL Limited, a global biotherapeutics company, opened a new corporate office in the United Kingdom for its influenza vaccine business Seqirus, according to a Dec. 3, 2015 press release from the company. Gordon Naylor, President of Seqirus and former Chief Financial Officer of CSL, said the UK office is the new corporate headquarters for the company.
Seqirus is the world’s second largest producer of influenza vaccines, with commercial presence in approximately 20 countries with more than 2000 employees. The company has manufacturing facilities in the United States, Australia, and the UK.
The company was formed in July 2015, after Novartis completed the divestiture of their influenza vaccine business to CSL for $275 million. Seqirus was created after the acquisition, as an integration of bioCSL and Novartis.
Seqirus recently received FDA approval for Fluad, a trivalent vaccine produced from three influenza strains. The vaccine was approved in November 2015 for the prevention of seasonal flu in people 65 years of age and older.